Semaglutide
semaglutide
glp-1 agonist
Semaglutide is a GLP-1 receptor agonist with a deep modern evidence base in obesity, diabetes, and cardiometabolic risk.
fat-loss|metabolism|cardiometabolic
Semaglutide mimics GLP-1 signaling to slow gastric emptying, reduce appetite, improve glucose regulation, and influence central satiety pathways.
Approved Drug Level | FDA Approved
metabolic-stack|advanced-metabolic-stack
fat-loss|metabolism|cardiometabolic|diabetes
semaglutide-vs-tirzepatide|aod-9604-vs-semaglutide
/images/semaglutide.jpg
published